101.83
-0.91(-0.89%)
Currency In USD
| Previous Close | 102.74 |
| Open | 102.44 |
| Day High | 102.82 |
| Day Low | 100.2 |
| 52-Week High | 124.49 |
| 52-Week Low | 29.17 |
| Volume | 1.69M |
| Average Volume | 3.35M |
| Market Cap | 19.69B |
| PE | -19.62 |
| EPS | -5.19 |
| Moving Average 50 Days | 93.51 |
| Moving Average 200 Days | 57.32 |
| Change | -0.91 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $3,523.53 as of February 21, 2026 at a share price of $101.83. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 5 years ago, it would be worth $2,293.47 as of February 21, 2026 at a share price of $101.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
GlobeNewswire Inc.
Feb 18, 2026 9:05 PM GMT
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report fina
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 9:05 PM GMT
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith,
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
GlobeNewswire Inc.
Jan 29, 2026 1:00 PM GMT
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-h